Loading... Please wait...
About Us
Contact Us
Privacy Policy
Sign in
or
Create an account
My Account
View Cart
Checkout
Search
Home
Therapy Area Reports
Browse by
Biosimilar Index
Dossier
FirstView
FirstView NPS+
FirstWord Pharma
Therapy Trends
Therapy Trends Updates
Latest Reports
Therapy Area Reports
Report Subject
Emerging Markets
Generics/Biosimilars
Market Access
Medical Affairs
Pharma Marketing
Pharma Sales
Technology/Digital Health
Orphan Drugs
Sort by:
Featured Items
Newest Items
Bestselling
Alphabetical: A to Z
Alphabetical: Z to A
Next »
Pages:
1
2
3
4
5
6
Learn More
Renal Cell Carcinoma: Update Bulletin [September 2017]
This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; data released from Bristol-Myers Squibb’s Phase III CheckMate-214 study,...
Compare
Learn More
Multiple Myeloma: Update Bulletin [September 2017]
This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; positive topline results from the Phase III study ALCYONE of Johnson &...
Compare
Learn More
Rheumatoid Arthritis: Update Bulletin [September 2017]
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of rheumatoid arthritis (RA). Topics covered in this update bulletin include expert opinions on; Johnson & Johnson...
Compare
Learn More
Payer Insights: RA : Update Bulletin [August 2017]
This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent approvals for biosimilar rituximab products in Europe Celltrion/Mundipharma’s Truxima...
Compare
Learn More
Melanoma: KOL Insight: Update Bulletin [August 2017]
This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma submission of two New Drug Applications (NDAs) to the US Food and...
Compare
Learn More
HNSCC: Update Bulletin [August 2017]
Gain new KOL insights on the latest events happening in head and neck squamous cell carcinoma (HNSCC): data from the Phase I/II ECHO-202/KEYNOTE-037 study of Incyte’s IDO1 inhibitor epacadostat in combination with...
Compare
Learn More
Breast Cancer: Update Bulletin [August 2017]
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY...
Compare
Learn More
NASH: Update Bulletin [August 2017]
Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include expert opinions on the recent...
Compare
Learn More
Multiple Sclerosis: Update Bulletin [August 2017]
This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche...
Compare
Learn More
Acute Myeloid Leukaemia: Update Bulletin [August 2017]
This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) space. Topics covered include expert opinions on; Seattle Genetics reporting the...
Compare
Learn More
Cystic Fibrosis: Update Bulletin [August 2017]
This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; Anthera Pharmaceuticals announcing that it has commenced...
Compare
Learn More
CAR-T Therapy in Haematological Malignancy: Update Bulletin [July 2017]
This edition presents US and EU key opinion leader (KOL) views on recent developments in the CAR-T therapy space. Topics covered include expert opinions on Novartis receiving a positive recommendation from the...
Compare
Learn More
COPD: Update Bulletin [July 2017]
Gain new key opinion leader (KOL) insights on the latest events happening in COPD. Topics covered include expert opinions on Sunovion’s SUN-101 (glycopyrrolate), delivered via PARI's investigational eFlow...
Compare
Learn More
Ovarian Cancer: Update Bulletin [July 2017]
This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaro's PARP inhibitor Zejula (niraparib)...
Compare
Learn More
Prostate Cancer: Update Bulletin [July 2017]
Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating...
Compare
Learn More
Targeted Therapies in Asthma: Update Bulletin [July 2017]
This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the severe asthma treatment landscape. Topics covered include; Novartis...
Compare
Learn More
Colorectal Cancer: Update Bulletin [June 2017]
This edition presents key opinion leader (KOL) views on recent developments in the Colorectal Cancer (CRC) market. Topics covered include: Bristol-Myers Squibb (BMS) announcing interim data from the Phase II,...
Compare
Learn More
Rheumatoid Arthritis: Update Bulletin [June 2017]
This edition presents key opinion leader (KOL) views on recent developments in the treatment of rheumatoid arthritis (RA). Topics covered include; KOL views on the Food and Drug Administration’s issuance of a...
Compare
Learn More
Ulcerative Colitis: Update Bulletin [June 2017]
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world...
Compare
Learn More
Type 2 Diabetes Mellitus KOL Insight : Update Bulletin [June 2017]
This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include: AstraZeneca’s announcement of positive top-line results from the Phase...
Compare
Next »
Pages:
1
2
3
4
5
6
About Us
Contact Us
Privacy Policy
customer.service@firstwordpharma.com
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved